The Brain Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Brain Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Brain Cancer. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Brain Cancer and features dormant and discontinued products.
GlobalData tracks 138 drugs in development for Brain Cancer by 128 companies/universities/institutes. The top development phase for Brain Cancer is preclinical with 70 drugs in that stage. The Brain Cancer pipeline has 119 drugs in development by companies and 19 by universities/ institutes. Some of the companies in the Brain Cancer pipeline products market are: Bristol-Myers Squibb, Celprogen and Moleculin Biotech.
The key targets in the Brain Cancer pipeline products market include Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22), Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22), and Smoothened Homolog (Protein Gx or SMO).
The key mechanisms of action in the Brain Cancer pipeline product include Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) Inhibitor with six drugs in Phase II. The Brain Cancer pipeline products include 20 routes of administration with the top ROA being Oral and 16 key molecule types in the Brain Cancer pipeline products market including Small Molecule, and Monoclonal Antibody.
Brain Cancer overview
Brain cancer refers to the abnormal growth of cells in the brain, forming tumors that can be benign (non-cancerous) or malignant (cancerous). Primary brain tumors originate in the brain itself, while secondary tumors result from the spread of cancer from other parts of the body. Symptoms may include headaches, seizures, changes in behavior, and cognitive impairment. Diagnosis involves imaging studies like MRI or CT scans, and treatment options vary depending on the tumor type, location, and grade. Treatment may include surgery, radiation therapy, chemotherapy, or a combination of these. Prognosis and outcomes depend on factors like tumor type, stage, and the effectiveness of treatment.
For a complete picture of Brain Cancer’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
